hC Bioscience

hC Bioscience

hC Bioscience operates out of Cambridge, Massachusetts, as a preclinical biotech company focused on tRNA-based therapeutics for protein restoration. The company was co-founded by Michael Koeris and John Ripple to advance a platform that treats nonsense mutations — the genetic errors that introduce premature stop codons and truncate essential proteins — by engineering suppressor tRNAs that read through those faulty signals. This approach is designed to correct disease at the protein level without permanently altering a patient's DNA. The firm's strategy centers on a single modality: engineered transfer RNA. Three primary disease areas anchor the pipeline: Dravet syndrome, cystic fibrosis, and certain oncological targets where nonsense mutations drive pathology. Stage coverage is exclusively preclinical, with lead programs advancing through in vivo proof-of-concept studies. The company has not disclosed a fund structure or outside capital-raising vehicle, but its operations have been supported by venture financing rounds, including a Series A led by Arch Venture Partners and Takeda Ventures, and a later round that brought in Taiho Ventures and other biotech specialist investors. Research partnerships with academic institutions supplement internal development. Geographic focus remains US-centric, with discovery work conducted in Cambridge. Leslie Williams joined as President and CEO in 2022, succeeding co-founder Michael Koeris, who transitioned to the role of Executive Chairman. Williams arrived from Immunovant, where she had served as Chief Operating Officer, bringing operational experience in shepherding rare-disease assets toward the clinic. Team size and deployment totals are not publicly disclosed. No adjacent philanthropic vehicles, club memberships, or operating businesses have been reported. In August 2023, the company presented preclinical data at the American Society of Gene and Cell Therapy annual meeting showing that its engineered tRNA restored protein expression in cellular models of Dravet syndrome (per the firm's official communications, 2023). hC Bioscience's structural differentiator is its focus on the proteome rather than the genome. Unlike gene therapy or CRISPR editors — which must deliver large, complex payloads into the nucleus — suppressor tRNA therapy operates in the cytoplasm using the cell's own translation machinery. This molecular architecture aims to bypass the delivery and immunogenicity challenges that have constrained genetic medicines, though the approach has yet to be validated in human trials. The company's long-run viability depends on translating its preclinical data into clinical proof of concept, a milestone that remains on the horizon.